NASDAQ:ABEO Abeona Therapeutics (ABEO) Stock Price, News & Analysis $5.00 -0.13 (-2.44%) As of 11:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Abeona Therapeutics Stock (NASDAQ:ABEO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Abeona Therapeutics alerts:Sign Up Key Stats Today's Range$5.03▼$5.1850-Day Range$5.04▼$6.0252-Week Range$3.05▼$8.45Volume159,998 shsAverage Volume327,808 shsMarket Capitalization$217.14 millionP/E RatioN/ADividend YieldN/APrice Target$17.50Consensus RatingBuy Company OverviewAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Read More… Remove Ads Abeona Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreABEO MarketRank™: Abeona Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 210th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAbeona Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbeona Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Abeona Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Abeona Therapeutics are expected to decrease in the coming year, from ($1.16) to ($1.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abeona Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Abeona Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbeona Therapeutics has a P/B Ratio of 8.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Abeona Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.56% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Abeona Therapeutics has recently increased by 2.02%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbeona Therapeutics does not currently pay a dividend.Dividend GrowthAbeona Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.03 Percentage of Shares Shorted6.56% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Abeona Therapeutics has recently increased by 2.02%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment0.46 News SentimentAbeona Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Abeona Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for ABEO on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Abeona Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,920.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of Abeona Therapeutics is held by insiders.Percentage Held by Institutions80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abeona Therapeutics' insider trading history. Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ABEO Stock News HeadlinesEarnings call transcript: Abeona Therapeutics reports Q4 2024 EPS beatMarch 22 at 4:49 PM | uk.investing.comOppenheimer maintains Abeona Therapeutics Outperform ratingMarch 22 at 4:49 PM | uk.investing.comTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.March 25, 2025 | Porter & Company (Ad)Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2024 Earnings Call TranscriptMarch 22 at 4:49 PM | msn.comAlliance Global Partners Sticks to Its Buy Rating for vTv Therapeutics (VTVT)March 22 at 1:45 AM | markets.businessinsider.comAbeona Therapeutics: Positive Outlook Amid FDA HopesMarch 21, 2025 | tipranks.comAbeona Therapeutics Inc.: Abeona Therapeutics Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch PlansMarch 21, 2025 | finanznachrichten.deAbeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparationsMarch 21, 2025 | msn.comSee More Headlines ABEO Stock Analysis - Frequently Asked Questions How have ABEO shares performed this year? Abeona Therapeutics' stock was trading at $5.57 on January 1st, 2025. Since then, ABEO shares have decreased by 8.5% and is now trading at $5.0950. View the best growth stocks for 2025 here. How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc (NASDAQ:ABEO) issued its quarterly earnings data on Thursday, March, 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.19. When did Abeona Therapeutics' stock split? Abeona Therapeutics shares reverse split before market open on Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Abeona Therapeutics' major shareholders? Top institutional investors of Abeona Therapeutics include Adage Capital Partners GP L.L.C. (8.98%), Millennium Management LLC (4.87%), Western Standard LLC (4.80%) and Rosalind Advisors Inc. (4.15%). Insiders that own company stock include Vishwas Seshadri, Brendan M O'malley, Michael Amoroso, Christine Berni Silverstein, Faith L Charles and Mark Alvino. View institutional ownership trends. How do I buy shares of Abeona Therapeutics? Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), CymaBay Therapeutics (CBAY) and General Electric (GE). Company Calendar Last Earnings3/20/2025Today3/25/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CIK318306 Webwww.abeonatherapeutics.com Phone214-665-9495Fax214-905-5101EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$17.50 High Stock Price Target$21.00 Low Stock Price Target$15.00 Potential Upside/Downside+250.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-203.27% Return on Assets-64.56% Debt Debt-to-Equity Ratio0.31 Current Ratio6.12 Quick Ratio6.12 Sales & Book Value Annual Sales$3.50 million Price / Sales62.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book8.33Miscellaneous Outstanding Shares43,471,000Free Float41,124,000Market Cap$217.14 million OptionableOptionable Beta1.79 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:ABEO) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.